找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Biomarkers in Liver Disease; Vinood B. Patel,Victor R. Preedy Reference work 2017 Springer Science+Business Media Dordrecht 2017 Applicati

[復制鏈接]
樓主: False-Negative
21#
發(fā)表于 2025-3-25 04:33:19 | 只看該作者
Interaction of Sialyltransferases, Sialidases, and Sialic Acids in Liver Diseases and Applications teen evaluated in liver diseases, and significant alterations have been found. Detailed understanding of the role of sialic acid, sialidases, and sialyltransferases and their interactions in liver diseases may significantly contribute to open new exciting frontiers of basic and therapeutic exploratio
22#
發(fā)表于 2025-3-25 10:08:09 | 只看該作者
AST-to-Platelet Ratio Index (APRI) as Marker in Liver Diseaseant fibrosis. It showed promising results for predicting the presence of fibrosis in pediatric patients with NAFLD. Transient elastography, a noninvasive and objective but expensive method, showed higher performance in diagnosing significant fibrosis than APRI.
23#
發(fā)表于 2025-3-25 13:08:00 | 只看該作者
Soluble CD163 (sCD163): Biomarker of Kupffer Cell Activation in Liver Diseasecant fibrosis exceeding standard diagnostic scores such as APRI and FIB-4. Lower levels are found in nonalcoholic fatty liver disease (NAFLD), but sCD163 adds diagnostic information on the important identification of patients with advanced disease..The emerging picture from the increasing number of
24#
發(fā)表于 2025-3-25 16:06:59 | 只看該作者
CD133 and EpCAM as Biomarkers in Liver Diseasesdifferentiation, migration, and cell survival. Wnt/β-catenin signaling pathway is the major pathway involved in EpCAM-positive hepatic cancers. CD133 and EpCAM have several significant clinical implications in diagnosis, prognosis, and therapy of human liver cancers. Recently defined histological ty
25#
發(fā)表于 2025-3-25 22:07:21 | 只看該作者
Graft-Derived Cell-Free DNA as a Biomarker in Liver Transplantationr more effective treatment intervention. It is especially helpful to guide changes in immunosuppression and to monitor immunosuppression minimization. This new approach may contribute to achieve more effective, less toxic personalized immunosuppression.
26#
發(fā)表于 2025-3-26 03:37:14 | 只看該作者
https://doi.org/10.1007/978-94-007-7675-3Application to prognosis; Biomarkers in disease; Cancer Research; Discovery of biomarkers; High throughp
27#
發(fā)表于 2025-3-26 06:52:39 | 只看該作者
28#
發(fā)表于 2025-3-26 11:33:23 | 只看該作者
29#
發(fā)表于 2025-3-26 13:14:09 | 只看該作者
Biomarkers in Disease: Methods, Discoveries and Applicationshttp://image.papertrans.cn/b/image/187816.jpg
30#
發(fā)表于 2025-3-26 18:11:27 | 只看該作者
 關于派博傳思  派博傳思旗下網站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網 吾愛論文網 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經驗總結 SCIENCEGARD IMPACTFACTOR 派博系數 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網安備110108008328) GMT+8, 2025-10-8 18:10
Copyright © 2001-2015 派博傳思   京公網安備110108008328 版權所有 All rights reserved
快速回復 返回頂部 返回列表
合水县| 同仁县| 陕西省| 呼和浩特市| 平乐县| 潮安县| 开鲁县| 易门县| 灵山县| 万山特区| 岑巩县| 卓资县| 柳江县| 滕州市| 建宁县| 沙洋县| 沽源县| 阳东县| 南郑县| 沾益县| 拉孜县| 厦门市| 贵溪市| 昆明市| 兰溪市| 东海县| 兖州市| 汉源县| 深水埗区| 东山县| 昌图县| 湘西| 永嘉县| 当涂县| 含山县| 海门市| 苍南县| 乃东县| 郓城县| 舒城县| 晋宁县|